Development of novel drugs for heart failure treatment based on modulating kinase activity of cardiac-MLCK

• Project/Area Number: 24790792
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Circulatory organs internal medicine
• Research Institution: National Cardiovascular Center Research Institute
• Principal Investigator: SEGUCHI Osamu 独立行政法人国立循環器病研究センター, 病院, 医師 (60570869)
• Co-Investigator(Renkei-kenkyūsha): KITAKAZE Masafumi 独立行政法人国立循環器病研究センター, 臨床研究開発基盤センター, 部長 (20294069) ; TAKASHIMA Seiji 大阪大学, 大学院医学系研究科医化学講座, 教授 (90379272)
• Project Period (FY): 2012-04-01 – 2014-03-31
• Project Status: Completed (Fiscal Year 2013)
• Budget Amount: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000); Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: 心不全 / 心筋症 / 遺伝子 / リン酸化酵素 / ペプチド創薬 / 創薬 / cardiac-MLCK

Research Abstract

The aim of this study is to develop novel drugs for heart failure which is increasing yearly in aging society of Japan.
We have previously identified novel cardiac-specific myosin light chain kinase (cardiac-MLCK) which is closely associated with the pathophysiology of heart failure. Recently, we also identified 8 unique peptide drugs suppressing kinase activity of cardiac-MLCK and we are investigating the pharmacologic effects of the peptide drugs for heart. These peptide drugs are expecting to become preventing drugs for heart failure through treating pathologic cardiac hypertrophy.

Research Products

• [Remarks] 研究会発表平成25年度Vascular Biology Innovation Conference 題名「心臓型MLCKと心不全、心筋症との関わり」